TITLE

Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance

AUTHOR(S)
Messori, A; Trippoli, S
PUB. DATE
May 2009
SOURCE
Heart;May2009, Vol. 95 Issue 10, p847
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66094671

 

Related Articles

  • NICE drug-eluting stents guidance the final word?  // PharmacoEconomics & Outcomes News;1/24/2009, Issue 570, p2 

    The article reports on the update published by the British National Institute for Clinical Excellence (NICE) to its guidance on the use of drug-eluting stents in July 2008. The conditions for using stents in percutaneous coronary intervention for the treatment of coronary artery disease are...

  • Commentary on drug-eluting stents: to use or not to use—that is the question! Pfisterer, Matthias E. // Heart;Dec2008, Vol. 94 Issue 12, p1648 

    The article presents the author's perspectives on the new guidance by the Great Britain National Institute for Health and Clinical Excellence (NICE) regarding the use of drug-eluting stents (DES) in percutaneous coronary intervention for the treatment of coronary artery disease. He contends that...

  • UK's NICE panel denies Cordis appeal of DES reimbursement.  // Medical Device Daily;8/11/2008, Vol. 12 Issue 173, p1 

    The article reports on the denial of an appeal by Cordis to the National Institute for Health and Clinical Excellence (NICE) regarding reimbursement for drug-eluting stent (DES) devices used in the treatment of coronary artery disease. Conditions of NICE for recommending DES use include the cost...

  • Commentary on drug-eluting stents: NICE technology appraisal guidance. Richardson, J.; Stevens, A.; Barnett, D.; Longson, C. // Heart;Dec2008, Vol. 94 Issue 12, p1650 

    The article discusses the circumstances that lead to the National Institute for Health and Clinical Excellence's (NICE) recommendations on the use of drug-eluting stents (DES) in Great Britain. The authors highlighted several evidence that the appraisal committee has considered in developing of...

  • Hydrophilic coating used on drug-eluting stent delivery system.  // Advanced Materials & Processes;Apr2012, Vol. 170 Issue 4, p15 

    The article reports that the hydrophilic technology from SurModics Inc. is used based in the Resolute Integrity Drug-Eluting Stent (DES) delivery system from Medtronic, which is used for coronary artery disease treatment.

  • UK's NICE panel turns down Cordis appeal of DES reimbursement. BROSKY, JOHN // Biomedical Business & Technology;Sep2008, Vol. 31 Issue 9, p22 

    The article reports on the decision of a panel of the British National Institute for Health and Clinical Excellence (NICE) to deny an appeal filed by Johnson & Johnson's (J&J) Cordis unit regarding reimbursement or drug-eluting stents (DES) used to treat coronary artery disease. It cites the...

  • Drug-eluting stents: A pharmacy management perspective. Baroletti, Steven A.; Maden, Atul // Formulary;Sep2004, Vol. 39 Issue 9, p446 

    Discusses the use of percutaneous coronary intervention in coronary artery disease. Evolution and pathophysiology of restenosis; Multiple aspects of drug-eluting stents technology; Benefits of stenting; Need to develop important adjunctive antiplatelet therapy protocols.

  • BOSTON SCIENTIFIC LAUNCHES TAXUS LIBERTE IN 18 COUNTRIES.  // Biotech Equipment Update;Mar2005, p1 

    The article reports that Boston Scientific Corp. has launched its TAXUS (TM) Liberte (TM) paclitaxel-eluting coronary stent system in 18 countries. The TAXUS Liberte stent system features the company's next-generation Liberte (TM) coronary stent. By combining the new Liberte stent with the...

  • UK panel turns down Cordis' appeal of DES reimbursement. BROSKY, JOHN // Cardiovascular Devices & Drugs;Sep2008, Vol. 14 Issue 9, p17 

    The article reports on the rejection by a panel of Britain's National Institute for Health and Clinical Excellence (NICE) of an appeal filed by Cordis regarding reimbursement for drug-eluting stents (DES) used to treat coronary artery disease. NICE issued a guidance that DES use would be...

  • Percutaneous coronary intervention and drug-eluting stents. Yi-ming Yang; Moussa, Issam // CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p323 

    Discusses the developments in percutaneous coronary interventions as of January 2005. Increase in the number of percutaneous coronary interventions performed each year in the U.S.; Significance of the advent of drug-eluting stents to the field of interventional cardiology; Principle of balloon...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics